1. Home
  2. KRNY vs ENTA Comparison

KRNY vs ENTA Comparison

Compare KRNY & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kearny Financial Corp

KRNY

Kearny Financial Corp

HOLD

Current Price

$7.98

Market Cap

504.9M

Sector

Finance

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.77

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRNY
ENTA
Founded
1884
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
504.9M
374.6M
IPO Year
2014
2012

Fundamental Metrics

Financial Performance
Metric
KRNY
ENTA
Price
$7.98
$14.77
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$8.00
$20.40
AVG Volume (30 Days)
286.4K
114.8K
Earning Date
04-23-2026
05-11-2026
Dividend Yield
5.47%
N/A
EPS Growth
130.22
29.93
EPS
0.30
N/A
Revenue
$2,580,000.00
$102,814,000.00
Revenue This Year
$3.89
$7.76
Revenue Next Year
$17.52
N/A
P/E Ratio
$26.80
N/A
Revenue Growth
36.00
16.48
52 Week Low
$5.76
$4.73
52 Week High
$8.50
$17.15

Technical Indicators

Market Signals
Indicator
KRNY
ENTA
Relative Strength Index (RSI) 61.88 66.38
Support Level $7.77 $13.39
Resistance Level $8.42 $15.52
Average True Range (ATR) 0.16 0.82
MACD 0.08 0.25
Stochastic Oscillator 76.47 94.87

Price Performance

Historical Comparison
KRNY
ENTA

About KRNY Kearny Financial Corp

Kearny Financial Corp is a federally-chartered stock savings bank. The bank is engaged in the business of attracting deposits from the general public in New Jersey and New York, and using these deposits, together with other funds, to originate or purchase loans for its portfolios and invest in securities. The bank's loan portfolio is chiefly comprised of loans collateralized by commercial and residential real estate. The bank's primary source of income is net interest income.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: